Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging - Takeaways - MDSpire

Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging

  • By

  • Jiaqi Xu

  • Jiawen Lin

  • Chao Ma

  • Jianishaya Yeerlan

  • Shuping Li

  • Wenjian Zhu

  • Zhihua Zheng

  • Mingcheng Huang

  • July 10, 2026

  • 0 min

Share

  • 1

    The study evaluated serum and urinary Golgi membrane protein 1 (GOLM1/GP73) as potential biomarkers for chronic kidney disease (CKD).

  • 2

    Serum G73 levels increased with CKD severity, while urinary G73 and the urine G73-to-creatinine ratio decreased significantly.

  • 3

    Adding serum G73 to clinical models improved the discrimination of advanced CKD, with an AUC increase from 0.81 to 0.85.

  • 4

    Serum G73 showed modest ability to distinguish acute kidney injury from chronic kidney disease, with AUC values ranging from 0.59 to 0.75.

  • 5

    The findings suggest that serum and urinary G73 could serve as non-invasive biomarkers to enhance CKD staging and clinical decision-making.

Original Source(s)

Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging

  • by Jiaqi Xu, Jiawen Lin, Chao Ma, Jianishaya Yeerlan, Shuping Li, Wenjian Zhu, Zhihua Zheng, Mingcheng Huang

  • July 10, 2026

Related Content

Raising the Profile of Collaborative Biostatisticians in Team Science

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Predicting propofol requirements in advanced gastrointestinal endoscopy: a validated model incorporating age and comorbidity index